In an earlier and now abandoned clinical trial programme, the ACE inhibitor imidapril had been studied in 200 patients with one of three cancer types, and improvement in body weight was reported in two (CRC and NSCLC) but not in the third type studied (pancreatic cancer) nor in the pre‐specified analysis of all three cancer types taken together.26 The gene discussed is ACE; the disease is familial pancreatic carcinoma.